Natco Pharma launches generic of Novartis’ immunosuppressant, partner to rollout product in U.S.

Natco Pharma on Friday announced launch of Everolimus tablets 1mg, a generic version of Novartis’ immunosuppressant Zortress.

Towa International’s U.S. subsidiary Breckenridge Pharmaceutical Inc., which is the marketing partner for the abbreviated new drug application (ANDA), plans to launch the product immediately in the U.S. market, Natco Pharma said.

Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation. Breckenridge previously launched Everolimus Tablets in 0.25mg, 0.5mg, and 0.75mg strengths, with blisters launched in July 2021 and bottles launched in June 2023, the company said.